Chronic infection with hepatitis C virus is a major cause of liver disease and hepatocellular
carcinoma worldwide. After the discovery of hepatitis C virus 3 decades ago, the …

Bicyclol, an innovative chemical drug with proprietary intellectual property rights in China, is
based on derivative of traditional Chinese medicine (TCM) Schisandra chinensis (Wuweizi) …

The approval of combination therapies with direct-acting antiviral (DAA) regimens has led to
significant progress in the field of hepatitis C virus (HCV) treatment. Although most patients …

Background & Aims People who inject drugs (PWID) and are on opioid agonist therapy
(OAT) might have lower adherence to direct-acting antivirals (DAAs) against hepatitis C virus …

Natural resistance-associated substitutions (RASs) are reported with highly variable
prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large …

Background Despite the high sustained virological response rates achieved with current
directly-acting antiviral agents (DAAs) against hepatitis C virus (HCV), around 5–10% of …

Bicyclol is a synthetic drug for hepatoprotection in clinic since 2004. Preliminary clinical
observations suggest that bicyclol might be active against hepatitis C virus (HCV) with …

Background & Aims Most hepatitis C virus (HCV)-infected patients failing NS5A inhibitors
develop resistance-associated substitutions (RASs). Here we report the use of resistance …

Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a
major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral …

While the prospect of viral cure is higher than ever for individuals infected with the hepatitis
C virus (HCV) due to ground-breaking progress in antiviral treatment, success rates are still …